Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Orphan Medical, Inc. (NasdaqNM:ORPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
13911 Ridgedale Drive, Suite 250
Minnetonka, MN 55305
Phone: (952) 513-6900
Fax: (952) 541-9209
Email: ir@orphan.com
Employees (last reported count): 57
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Products & Services
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 41%
·Institutional: 48% (81% of float)
(21 institutions)
·Net Inst. Buying: 1.31M shares (+24.34%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Orphan Medical, Inc. acquires, develops and markets products of high medical value for patients within selected strategic therapeutic market segments (STMS). The Company currently concentrates on drugs with high medical value that may be marketed within three selected STMS: Antidotes, Oncology Support, and Sleep Disorders. Antizol and Busulfex are commercially available and are the Company's lead products in its Antidote and Oncology Support STMS, respectively. Xyrem is an investigational drug and is expected to be the Company's lead product in its Sleep Disorders STMS. In addition, the Company manufactures and distributes Cystadane and Sucraid that treat two rare congenital diseases. Antizol-Vet is marketed through separate channels to the veterinary community although these products do not fall into any of the three selected STMS.
More from Market Guide: Expanded Business Description

Financial Summary
Orphan Medical acquires, develops and markets products of high medical value for patients within selected strategic therapeutic market segments. For the six months ended 6/30/01, revenues decreased 17% to $4.8 million. Net loss applicable to Common increased 52% to $3.5 million. Revenues reflect decreased sales of Antizol. Net loss reflects increased S/G/A expenses and a decreased gross profit due to a change in product mix.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

John Bullion, 49
Chairman, CEO, Sec.
$181K
Timothy McGrath, 36
CFO, VP
183K
William Houghton, M.D., 58
COO
226K
Patti Engel, 40
VP of Marketing and Sales
232K
Dayton Reardan, Ph.D., 45
VP of Regulatory Affairs
181K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ORPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 2-Mar-2001
$6.375
Recent Price$9.10 
52-Week High
on 29-Jan-2001
$18.375
Beta0.52 
Daily Volume (3-month avg)25.7K
Daily Volume (10-day avg)10.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-17.3%
52-Week Change
relative to S&P500
+11.0%
Share-Related Items
Market Capitalization$77.2M
Shares Outstanding8.48M
Float5.00M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.92 
Earnings (ttm)-$0.97 
Earnings (mrq)-$0.23 
Sales (ttm)$1.21 
Cash (mrq)$0.84 
Valuation Ratios
Price/Book (mrq)9.93 
Price/EarningsN/A 
Price/Sales (ttm)7.55 
Income Statements
Sales (ttm)$10.2M
EBITDA (ttm)-$7.88M
Income available to common (ttm)-$8.17M
Profitability
Profit Margin (ttm)-71.5%
Operating Margin (ttm)-78.1%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-49.37%
Return on Equity (ttm)-73.42%
Financial Strength
Current Ratio (mrq)2.31 
Debt/Equity (mrq)0 
Total Cash (mrq)$7.17M
Short Interest
As of 8-Aug-2001
Shares Short1,000 
Percent of Float0.0%
Shares Short
(Prior Month)
24.0K
Short Ratio0.08 
Daily Volume13.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.